331-345 of 894
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Vanessa Helou, MD
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
On the Frontlines of Prostate CancerActive Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Lisa Newcomb, PhD
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
On the Frontlines of Prostate CancerPersonalizing Prostate Cancer Surveillance: Insights from Canary PASS
Lisa Newcomb, PhD
- advertisement
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Deep Breaths: Updates from CHESTEvolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Gerard A. Silvestri MD, MS
Anurag Singh, MD
Adam H. Fox, MD, MSc
Mariam Alexander, MD, PhD
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Deep Breaths: Updates from CHESTUnderstanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Gerard A. Silvestri MD, MS
Anurag Singh, MD
Adam H. Fox, MD, MSc
Mariam Alexander, MD, PhD
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Project Oncology®Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Project Oncology®Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
On the Frontlines of Prostate CancerEvolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
Daniel J. George, MD
ADT Monotherapy for mHSPC: How to Identify the Right Patients
On the Frontlines of Prostate CancerADT Monotherapy for mHSPC: How to Identify the Right Patients
Daniel J. George, MD
- advertisement
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
On the Frontlines of Prostate CancerRedefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Daniel J. George, MD
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerAdvancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
Megan Kruse, MD
Optimizing Quality of Life in HER2+ Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerOptimizing Quality of Life in HER2+ Metastatic Breast Cancer
Megan Kruse, MD
